The company will spotlight the breast cancer risk stratification software Volpara Risk Pathways and a new mammography training collaboration with Mammography Educators.
Recognizing the shift from age-based breast cancer screening to screening programs that are more focused on risk stratification, Volpara will be spotlighting its Volpara Risk Pathways™ software at the annual Society of Breast Imaging (SBI)/American College of Radiology (ACR) conference in Savannah, Ga. this week.
Drawing upon patient data from mammography reporting systems or electronic health records, Volpara Risk Pathways reportedly facilitates the identification and management of patients who are at high risk for breast cancer, according to Volpara. The company said the software’s assessment of an individual’s risk for breast cancer enables enhanced triage decisions for supplemental imaging and/or genetic testing.
Volpara will also spotlight the Analytics in Action program, which offers on-site training from Mammography Educators.
“The Analytics in Action program is designed to help deliver high-quality, personalized breast cancer screening by improving image quality, reducing errors, and increasing proficiency and efficiency. We are excited for our partnership with Volpara to deliver hands-on, personalized training sessions designed not only to help address common positioning performance issues but also to create a culture of quality and continuous improvement that ultimately will result in better screening and better patient care,” noted Louise Miller, R.T. (R)(M)(ARRT), CRT, FSBI, FNCBC, the director of education and co-founder of Mammography Educators.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.